Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Lawrence Blonde, John E. Anderson, Pavan Chava & Jared A. Dendy. (2019) Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes. Current Medical Research and Opinion 35:5, pages 793-804.
Read now
Read now
Thorsten Otto, Melissa Myland, Heike Jung, Jeremie Lebrec, Hartmut Richter & Kirsi Norrbacka. (2019) Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study. Current Medical Research and Opinion 35:5, pages 893-901.
Read now
Read now
Ian Blumer, Jeremy H. Pettus & Tricia Santos Cavaiola. (2018) Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations. Postgraduate Medicine 130:4, pages 375-380.
Read now
Read now
Articles from other publishers (18)
Yanqing Jiang, Ruizhe Liu, Jianwei Xuan, Sisi Lin, Qiang Zheng & Jianxin Pang. (2023) A Cost-effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China. Clinical Drug Investigation 43:4, pages 251-263.
Crossref
Crossref
Ana Palanca, F. Javier Ampudia-Blasco, José Miguel Calderón, Inmaculada Sauri, Sergio Martinez-Hervás, José Luis Trillo, Josep Redón & José T. Real. (2023) Real-World Evaluation of GLP-1 Receptor Agonist Therapy Persistence, Adherence and Therapeutic Inertia Among Obese Adults with Type 2 Diabetes. Diabetes Therapy 14:4, pages 723-736.
Crossref
Crossref
Marc Evans, Susanne Engberg, Mads Faurby, João Diogo Da Rocha Fernandes, Pollyanna Hudson & William Polonsky. (2021) Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review. Diabetes, Obesity and Metabolism 24:3, pages 377-390.
Crossref
Crossref
Rory J. McCrimmon, Edel Falla, Jo Zhou Sha, Abdul Jabbar Omar Alsaleh, Elisheva Lew, Richard Hudson, Mike Baxter & Karen Palmer. (2021) Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK. Diabetes Therapy 12:12, pages 3217-3230.
Crossref
Crossref
Alexander Abitbol, Rick Siemens, Natalie Nightingale, John Stewart, Marie-Josée Toutounji & Ronald Goldenberg. (2021) Persistence of GLP-1 RA in combination with basal insulin among adults with type 2 diabetes in Canada. Diabetes Research and Clinical Practice 177, pages 108920.
Crossref
Crossref
William Polonsky, Cory Gamble, Neeraj Iyer, Mona Martin & Carol Hamersky. (2021) Exploring Why People With Type 2 Diabetes Do or Do Not Persist With Glucagon-Like Peptide-1 Receptor Agonist Therapy: A Qualitative Study. Diabetes Spectrum 34:2, pages 175-183.
Crossref
Crossref
Kirsi Norrbacka, Antoni Sicras-Mainar, Jeremie Lebrec, Esther Artime, Silvia Díaz, Santiago Tofé-Povedano, Ignacio Hernández & Irene Romera. (2021) Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain. Diabetes Therapy 12:5, pages 1535-1551.
Crossref
Crossref
Ann‐Marie Svensson, Anders Toll, Jeremie Lebrec, Mervete Miftaraj, Stefan Franzén & Björn Eliasson. (2020) Treatment persistence in patients with type 2 diabetes treated with glucagon‐like peptide‐1 receptor agonists in clinical practice in Sweden. Diabetes, Obesity and Metabolism 23:3, pages 720-729.
Crossref
Crossref
Christopher K. Rayner, Tongzhi Wu, Vanita R. Aroda, Craig Whittington, Steve Kanters, Patricia Guyot, Alka Shaunik & Michael Horowitz. (2020)
Gastrointestinal adverse events with insulin glargine/lixisenatide fixed‐ratio combination versus glucagon‐like peptide‐1 receptor agonist
s
in people with type 2 diabetes mellitus: A network meta‐analysis
. Diabetes, Obesity and Metabolism 23:1, pages 136-146.
Crossref
Crossref
Erica L. Stockbridge, Abiah D. Loethen, Esther Annan & Thaddeus L. Miller. (2020) Interferon gamma release assay tests are associated with persistence and completion of latent tuberculosis infection treatment in the United States: Evidence from commercial insurance data. PLOS ONE 15:12, pages e0243102.
Crossref
Crossref
Edward B. Jude, Mark Nixon, Caroline O’Leary, Melissa Myland, Nick Gooch, Alka Shaunik & Elisheva Lew. (2019) Evaluating Glycemic Control in Patients with Type 2 Diabetes Suboptimally Controlled on Basal Insulin: UK ATTAIN Real-World Study. Diabetes Therapy 10:5, pages 1847-1858.
Crossref
Crossref
Carol M. Hamersky, Moshe Fridman, Cory L. Gamble & Neeraj N. Iyer. (2019) Injectable Antihyperglycemics: A Systematic Review and Critical Analysis of the Literature on Adherence, Persistence, and Health Outcomes. Diabetes Therapy 10:3, pages 865-890.
Crossref
Crossref
Victoria Divino, Kristina S. Boye, Jeremie Lebrec, Mitch DeKoven & Kirsi Norrbacka. (2019) GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data. Diabetes Therapy 10:3, pages 1067-1088.
Crossref
Crossref
Cheli Melzer-Cohen, Gabriel Chodick, Lise Lotte N. Husemoen, Nicolai Rhee, Varda Shalev & Avraham Karasik. (2019) A Retrospective Database Study of Liraglutide Persistence Associated with Glycemic and Body Weight Control in Patients with Type 2 Diabetes. Diabetes Therapy 10:2, pages 683-696.
Crossref
Crossref
Joel Rodriguez-Saldana. 2019. The Diabetes Textbook. The Diabetes Textbook
381
400
.
G. Reach. (2018) Avant-propos: Pourquoi s’intéresser à l’observance ?. Médecine des Maladies Métaboliques 12:6, pages 468-472.
Crossref
Crossref
Fang Liz Zhou, Lin Xie, Chunshen Pan, Yuexi Wang, Neel Vaidya, Fen Ye, Ronald Preblick & Luigi Meneghini. (2018) Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiating basal insulin. Diabetes, Obesity and Metabolism 20:5, pages 1298-1301.
Crossref
Crossref
Marco Orsini Federici, Janette McQuillan, Giovanni Biricolti, Serena Losi, Jeremie Lebrec, Catrina Richards, Cristiana Miglio & Kirsi Norrbacka. (2018) Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study. Diabetes Therapy 9:2, pages 789-801.
Crossref
Crossref